Editor-in-Chief
Ufuk Demirkılıç
Frequency
Quarterly
Abbreviation
Turk J Vasc Surg
Publisher
Turkish National Vascular and Endovascular Surgery Society
ISSN
2667-4947
E-ISSN
2667-5080


Turkish Journal of Vascular Surgery
2013 , Vol 22 , Issue 1
Derin Ven Trombozlu Hastalarda Faktör V Leiden Mutasyonu Taraması ve Sonuçları
1Kalp Damar Cerrahisi AD, İnönü Üniversitesi Tıp Fakültesi, Malatya
DOI :
10.9739/uvcd.2012-32287
Objective: In this study, we aimed to investigate incidence of Factor V Leiden mutation
in patients with deep vein thrombosis. Material and Methods: Between January 2009 and August
2011, 53 patients with deep vein thrombosis were investigated for Factor V Leiden mutation.
Of all, 50.94% patients were males and age range was 19-83 years. All of the patients were hospitalized.
Standard IV heparine and warfarine were administered. Screening tests for etiology were
done for all patients. Results: Eleven patients were heterozygotes (7 males, 4 females) (20.75%), 2
patients were homozygotes (2 females) (%3.77). Pulmonary embolism was evident in 1 heterozygote
female patient. Of 6 patients with recurrent deep vein thrombosis, 1 heterozygote male and 1
homozygote female patients were detected. One of the patients with reccurent deep vein thrombosis
was a patient in the 6th decade and had malignancy. Deep vein thrombosis occured due to risk
factors such as immobilisation, pregnancy, postpartum period or maligancy in 6 patients. Femoral
veins were involved in all patients with factor V leiden mutation. Conclusion: Life time oral anticoagulation
therapy is inevitable in patients with Factor 5 leiden mutation especially with recurrent
deep vein thrombosis. Additionally; screening tests for family members must be considered. In
patients with high risk, genetic consultation is important for prophylaxis of deep vein thrombosis
and preparation for medical emergencies.
Keywords :
Factor V leiden; thromboembolism; deep venous thrombosis; prophylaxis
Viewed : 1738
Downloaded : 3652